Webinar
Enable Comprehensive Genomic Profiling with Product Updates on TruSight™ Oncology 500 v2
May 19, 2025 09:00 AM US/Pacific
TruSight™ Oncology 500 v2 (TSO500v2) is an updated next-generation sequencing (NGS) assay designed to enable laboratories with in-house comprehensive genomic profiling (CGP) from formalin-fixed, paraffin-embedded (FFPE) tissue samples. Building on the success of its predecessor, TSO500v2 targets 523 genes and assesses a wide range of biomarkers—including SNVs, CNVs, indels, fusions, Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), and Homologous Recombination Deficiency (HRD)—with enhanced sensitivity, coverage, scalability, scalability, and bioinformatics workflows.
This webinar will unveil the latest advancements in TSO500v2, showcasing its applications through oncology research insights. Join us to hear from experts at Illumina, Erasmus University Medical Center (Netherlands), and Instituto Catalan de Oncologia (Spain) as they present early performance data, including DNA, RNA and HRD analysis. Attendees will gain a practical understanding of the assay’s usability in the lab, its improvements over TSO500v1, and its relevance to clinical research and precision oncology. The session will conclude with a live Q&A to address your questions on product features and research implications.
Learning Objectives:
Discuss CGP capabilities for DNA and RNA from FFPE samples highlighting improvements over previous versions and relevance to clinical research and precision oncology
Showcase TSO 500 v2 performance in DNA analysis
Review a laboratory experience and kit usability of TSO 500 v2 RNA and HRD analysis capabilities using ICO data
Erik Jan Dubbink, PhD
Erik Jan Dubbink is deputy head of molecular diagnostics in the Pathology and Clinical Bioinformatics department at Erasmus University Medical Center located in Rotterdam, Netherlands. Renowned for his work on tumor genomics, he has driven the adoption of comprehensive genomic profiling in clinical diagnostics. With a wide experience in circulating tumor DNA (ctDNA) and homologous recombination deficiency (HRD), his research is shaping the future of non-invasive cancer monitoring and targeted therapies in precision medicine.
Ronald Van Marion
Ronald van Marion is a senior genomics researcher at the department of Pathology and Clinical Bioinformatics at Erasmus University Medical Center in Rotterdam, Netherlands. His work focuses on the application of high-throughput sequencing to unravel the genomic landscapes of complex diseases, particularly cancers. At Erasmus MC, he has been instrumental in validating NGS assays, bridging the gap between cutting-edge genomics and patient care.
Daniel Azuara
Daniel Azuara is a molecular biologist at the Institut Català d'Oncologia (ICO) in Barcelona, Spain, where he leads efforts in genomic profiling of tumors. With over a decade of experience, he has spearheaded the integration of next-generation sequencing (NGS) technologies, like the Comprehensive Genomic Profiling, into clinical workflows, enabling precise identification of actionable mutations in cancer patients and advancing personalized oncology.